Wholly-owned Subsidiary’s CS12088 Clinical Trial Application Accepted
December 14, 2024
Source: drugdu
49
According to a news report on December 10, ChipScreen Biotech announced that its wholly-owned subsidiary, Chengdu ChipScreen Pharmaceuticals Co., Ltd., recently received the Acceptance Notice for the clinical trial registration of domestically-produced drugs issued by the National Medical Products Administration (NMPA) Drug Review Center. The clinical trial application for CS12088 has been accepted by the NMPA Drug Review Center.
CS12088 is classified as an HBV core assembly modulator, featuring significant antiviral activity, liver-targeting characteristics, and good safety and tolerability. This medication works by interfering with the assembly of the HBV core, blocking the packaging of the viral pre-genomic RNA into the core, which in turn inhibits the replication of HBV DNA and suppresses the production of mature viral particles. The company will actively advance this research and development project and will strictly comply with relevant regulations to timely fulfill its disclosure obligations regarding the subsequent progress of the project.
https://finance.eastmoney.com/a/202412103264202237.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
